Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas, Edson D. Moreira Jr., Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbini, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper, Robert W. Frenck Jr., Laura L. Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Qi Yang, Paul Liberator, Dina B. Tresnan, Susan Mather, Philip R. Dormitzer, Uğur Şahin, William C. Gruber, Kathrin U. Jansen, C4591001 Clinical Trial Group
doi: https://doi.org/10.1101/2021.07.28.21261159
Stephen J. Thomas
1State University of New York, Upstate Medical University, Syracuse, NY
M.D.Edson D. Moreira Jr.
2Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia, Brazil
M.D.Nicholas Kitchin
3aVaccine Research and Development, Pfizer Inc, Hurley, UK
M.D.Judith Absalon
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
M.D.Alejandra Gurtman
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
M.D.Stephen Lockhart
3aVaccine Research and Development, Pfizer Inc, Hurley, UK
D.M.John L. Perez
3cVaccine Research and Development, Pfizer Inc, Collegeville, PA
M.D.Gonzalo Pérez Marc
4iTrials-Hospital Militar Central, Buenos Aires, Argentina
M.D.Fernando P. Polack
5Fundacion INFANT, Buenos Aires, Argentina
M.D.Cristiano Zerbini
6Centro Paulista de Investigação Clinica, São Paulo, Brazil
M.D.Ruth Bailey
3aVaccine Research and Development, Pfizer Inc, Hurley, UK
B.Sc.Kena A. Swanson
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Xia Xu
3cVaccine Research and Development, Pfizer Inc, Collegeville, PA
Ph.D.Satrajit Roychoudhury
7Global Product Development, Pfizer Inc, Peapack, NJ
Ph.D.Kenneth Koury
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Salim Bouguermouh
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
M.D., Ph.D.Warren V. Kalina
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.David Cooper
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Robert W. Frenck Jr.
8Cincinnati Children’s Hospital, Cincinnati, OH
M.D.Laura L. Hammitt
9Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
M.D.Özlem Türeci
10BioNTech, Mainz, Germany
M.D.Haylene Nell
11Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town, South Africa
M.D.Axel Schaefer
12Medizentrum Essen Borbeck, Essen, Germany
M.D.Serhat Ünal
13Hacettepe University, Ankara, Turkey
M.D.Qi Yang
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Paul Liberator
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Dina B. Tresnan
14aWorldwide Safety, Safety Surveillance and Risk Management, Pfizer, Inc, Groton, CT
D.V.M., Ph.D.Susan Mather
14bWorldwide Safety, Safety Surveillance and Risk Management, Pfizer, Inc, Collegeville, PA
M.D.Philip R. Dormitzer
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
M.D., Ph.D.Uğur Şahin
10BioNTech, Mainz, Germany
M.D.William C. Gruber
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
M.D.Kathrin U. Jansen
3bVaccine Research and Development, Pfizer Inc, Pearl River, NY
Ph.D.Article usage
Posted July 28, 2021.
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas, Edson D. Moreira Jr., Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbini, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper, Robert W. Frenck Jr., Laura L. Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Qi Yang, Paul Liberator, Dina B. Tresnan, Susan Mather, Philip R. Dormitzer, Uğur Şahin, William C. Gruber, Kathrin U. Jansen, C4591001 Clinical Trial Group
medRxiv 2021.07.28.21261159; doi: https://doi.org/10.1101/2021.07.28.21261159
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas, Edson D. Moreira Jr., Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L. Perez, Gonzalo Pérez Marc, Fernando P. Polack, Cristiano Zerbini, Ruth Bailey, Kena A. Swanson, Xia Xu, Satrajit Roychoudhury, Kenneth Koury, Salim Bouguermouh, Warren V. Kalina, David Cooper, Robert W. Frenck Jr., Laura L. Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Qi Yang, Paul Liberator, Dina B. Tresnan, Susan Mather, Philip R. Dormitzer, Uğur Şahin, William C. Gruber, Kathrin U. Jansen, C4591001 Clinical Trial Group
medRxiv 2021.07.28.21261159; doi: https://doi.org/10.1101/2021.07.28.21261159
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (708)
- Anesthesia (201)
- Cardiovascular Medicine (2930)
- Dermatology (249)
- Emergency Medicine (439)
- Epidemiology (12734)
- Forensic Medicine (12)
- Gastroenterology (827)
- Genetic and Genomic Medicine (4577)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2914)
- Health Policy (1069)
- Hematology (388)
- HIV/AIDS (924)
- Medical Education (424)
- Medical Ethics (115)
- Nephrology (468)
- Neurology (4344)
- Nursing (236)
- Nutrition (638)
- Oncology (2266)
- Ophthalmology (645)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (500)
- Pediatrics (1196)
- Primary Care Research (495)
- Public and Global Health (6932)
- Radiology and Imaging (1525)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (487)
- Toxicology (60)
- Transplantation (210)
- Urology (180)